Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Liminal BioSciences Inc. (T:LMNL)

Business Focus: N/A

Jul 22, 2020 07:55 am ET
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
LAVAL, QC and CAMBRIDGE, England, July 22, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announces that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020.
Jul 22, 2020 07:55 am ET
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
LAVAL, QC and CAMBRIDGE, England, July 22, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announces that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020.
Jul 17, 2020 08:00 am ET
Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases
LAVAL, QC and CAMBRIDGE, England, July 17, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases throug
Jul 17, 2020 08:00 am ET
Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases
LAVAL, QC and CAMBRIDGE, England, July 17, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases throug
Jul 02, 2020 11:16 am ET
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
Jul 02, 2020 11:16 am ET
Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
Jun 30, 2020 05:31 pm ET
Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.
Jun 30, 2020 05:31 pm ET
Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.
Jun 30, 2020 05:00 pm ET
Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020
LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today provided a guidance update on the timing of certain expected key milestones for 2020.
Jun 30, 2020 05:00 pm ET
Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020
LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today provided a guidance update on the timing of certain expected key milestones for 2020.
Jun 11, 2020 05:00 pm ET
Liminal BioSciences to Present at Raymond James Human Health Innovation Conference
LAVAL, QC and CAMBRIDGE, United Kingdom, June 11, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at Raymond James Human Health Innovation Conference on Thursday 18th June at 13:00 (EDT).
Jun 11, 2020 05:00 pm ET
Liminal BioSciences to Present at Raymond James Human Health Innovation Conference
LAVAL, QC and CAMBRIDGE, United Kingdom, June 11, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at Raymond James Human Health Innovation Conference on Thursday 18th June at 13:00 (EDT).
Jun 09, 2020 03:53 pm ET
Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)
LAVAL, QC and CAMBRIDGE, United Kingdom, June 9, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually on June 8, 2020. A total of 20,352,943 common shares were voted, representing 86.90% of the votes attached to the issued and outstanding common shares of Liminal BioSciences.
Jun 09, 2020 03:53 pm ET
Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)
LAVAL, QC and CAMBRIDGE, United Kingdom, June 9, 2020 /CNW/ - Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually on June 8, 2020. A total of 20,352,943 common shares were voted, representing 86.90% of the votes attached to the issued and outstanding common shares of Liminal BioSciences.
May 28, 2020 05:30 pm ET
Liminal BioSciences to present at Jefferies Virtual Healthcare Conference
LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at Jefferies Virtual Healthcare Conference on Thursday 4th June at 14:30.
May 28, 2020 05:30 pm ET
Liminal BioSciences to present at Jefferies Virtual Healthcare Conference
LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at Jefferies Virtual Healthcare Conference on Thursday 4th June at 14:30.
May 13, 2020 05:00 pm ET
Liminal Biosciences Reports Q1 2020 Results
LAVAL, QC, and CAMBRIDGE, United Kingdom, May 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today reported its financial results for the first quarter ended March 31, 2020.
May 13, 2020 05:00 pm ET
Liminal Biosciences Reports Q1 2020 Results
LAVAL, QC, and CAMBRIDGE, United Kingdom, May 13, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today reported its financial results for the first quarter ended March 31, 2020.
Mar 22, 2020 03:23 pm ET
Liminal BioSciences comments on Coronavirus (COVID-19)
Measures taken to safeguard workforce and continuity of operations Recent FDA update on continued efforts to facilitate development of treatments LAVAL, QC, and CAMBRIDGE, UK, March 22, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, commented today on the impact of the cur
Mar 22, 2020 03:23 pm ET
Liminal BioSciences comments on Coronavirus (COVID-19)
Measures taken to safeguard workforce and continuity of operations Recent FDA update on continued efforts to facilitate development of treatments LAVAL, QC, and CAMBRIDGE, UK, March 22, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, commented today on the impact of the cur
Mar 20, 2020 05:00 pm ET
Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast
LAVAL, QC and CAMBRIDGE, United Kingdom, March 20, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, announced today it will report its financial results for the fourth quarter and financial year ended December 31, 2019 on Friday March 20, 2020 after market close.
Mar 20, 2020 05:00 pm ET
Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast
LAVAL, QC and CAMBRIDGE, United Kingdom, March 20, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, announced today it will report its financial results for the fourth quarter and financial year ended December 31, 2019 on Friday March 20, 2020 after market close.
Feb 12, 2020 06:30 am ET
Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia
FIBROSIS AND TISSUE REPAIR OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Feb. 12, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the Company and its collaborators will present scientific findings at two upcoming Keystone Symposia : (i)  Fibrosis and Tissue Repair: From Molecules and Mechanics to
Feb 06, 2020 06:30 am ET
Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Feb. 6, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the BIO CEO & Investor Conference taking place February 10-11, 2020 in New York, USA. The presentation will take place on Monday, February 10th at 10:15 AM
Jan 13, 2020 06:00 am ET
Liminal BioSciences Outlines Corporate Priorities for 2020
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Jan. 13, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today provided a corporate update and outlined its key corporate and R&D priorities for 2020.
Dec 23, 2019 02:43 pm ET
Liminal BioSciences Comments on Unusual Market Activity
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK, Dec. 23, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company"), is issuing this news release in light of unusual trading activity related to the common shares of the Company (the "Shares") on the Toronto Stock Exchange ("TSX") and Nasdaq. While Liminal BioSciences does not normally comment on market activity, Liminal BioSciences confirms that it is not aware of any undisclosed material change in the business, operations or affairs of Liminal BioSciences that would account for the recent in
Nov 28, 2019 03:40 pm ET
AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 28, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorité des Marchés Financiers ("AMF") in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection wi
Nov 27, 2019 06:30 am ET
Liminal BioSciences to Present at Piper Jaffray Healthcare Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 27, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today, today announced that members of the management team will provide a business overview and update at the Piper Jaffray 31st Annual Healthcare Conference at 08:10 ET on Wednesday, December 4, 2019 in New York, USA.
Nov 25, 2019 11:03 am ET
Liminal BioSciences announces closing of divestiture of bioseparations division to KKR
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK, Nov. 25, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. ("PBL") to KKR & Co., a leading global investment firm ("KKR").
Nov 18, 2019 07:05 pm ET
Liminal Presents New Preclinical Data on PBI-4050 and its Effect on Angio-Proliferative Pulmonary Arterial Hypertension
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK, Nov. 18, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL)  ("Liminal BioSciences" or the "Company"), a clinical-stage biotechnology company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today the presentation of two scientific posters with new preclinical data for PBI-4050 and the treatment of pulmonary arterial hypertension ("PAH") at the American Heart Association ("AHA") 2019 conference taking place on November 16-18, 2019 in Philadelphia, PA
Nov 18, 2019 05:00 pm ET
Liminal BioSciences to Present at the Jefferies 2019 London Healthcare Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 18, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biotechnology company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today, today announced that members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 18:00 GMT on Wednesday, November 20, 2019 in London, UK.
Nov 18, 2019 06:30 am ET
Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 18, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biotechnology company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that its registration statement on Form F-10 (the "Registration Statement"), which was filed with the United States Securities and Exchange Commission (the "SEC") on November 12, 2019 under the Canada-U.S. multijurisdictional disclosure system, w
Nov 15, 2019 05:30 pm ET
Liminal BioSciences to Present at Stifel Healthcare Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 15, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (NASDAQ: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that members of the management team will provide a business overview and update at the Stifel Healthcare Conference at 14:25 ET on Tuesday, November 19, 2019 in New York, USA.
Nov 15, 2019 06:30 am ET
Liminal BioSciences to Commence Trading Common Shares on NASDAQ
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 15, 2019 /PRNewswire/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission ("SEC"),which has become effective, and its common shares have been approved for trading on the Nasdaq Global Market ( "NASDAQ"). Trading is
Nov 15, 2019 06:30 am ET
Liminal BioSciences to Commence Trading Common Shares on NASDAQ
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 15, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission ("SEC"),which has become effective, and its common shares have been approved for trading on the Nasdaq Global Market ( "NASDAQ"). Trading is
Nov 14, 2019 04:50 pm ET
/C O R R E C T I O N from Source -- Liminal BioSciences Inc./
In the news release, Liminal BioSciences Reports its 2019 Third Quarter Financial Results and Business Highlights, issued 11-Nov-2019 by Liminal BioSciences Inc. over CNW, we are advised by the company that an error occurred in the third bullet of the subheadline. The sentence should read "... compared to Net loss of $28.9 million for Q3 2018" rather than ''... compared to Net loss of $33.2 million for Q3 2018'' as originally issued inadvertently. The complete, corrected release follows:
Nov 13, 2019 06:30 am ET
Liminal Biosciences Announces Key Appointment to its Leadership Team
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 13, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL), (OTCQX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today the addition of Moira Daniels as the new Head of Regulatory Affairs and Quality Assurance, to its senior leadership team.
Nov 12, 2019 06:10 pm ET
Liminal BioSciences Presents New Preclinical Data on PBI-4050 and NASH Candidate PBI-4547
New preclinical data suggests PBI-4547 displays pleiotropic activities and has been shown to reduce non-alcoholic steatohepatitis (NASH), diabetes and fibrosis in different rodent models. LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 12, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today the presentation of three scientific posters with new
Nov 11, 2019 05:16 pm ET
Liminal BioSciences to Report Q3 2019 Results and Hold Conference Call
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 11, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it will report its financial results for the third quarter ended September 30th 2019 on Monday November 11, 2019 after market close.
Nov 11, 2019 05:10 pm ET
Liminal BioSciences Reports its 2019 Third Quarter Financial Results and Business Highlights
Name change to Liminal BioSciences Inc. Divestment of UK bioseparations subsidiary to KKR for up to GBP 45 million in gross proceeds, of which GBP 32 million to be received upon closing Net loss of $29.7 million for Q3 2019 compared to Net loss of $33.2 million for Q3 2018 Amendment to Consolidated loan agreement with Structured Alpha LP to provide non-revolving $75 million line of credit. LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 11, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biotechn
Nov 11, 2019 06:30 am ET
Liminal Biosciences Presents New Preclinical Data at ASN Kidney Week 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 11, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the Company and its' collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology's ("ASN") Kidney Week 2019 taking place from No
Nov 04, 2019 06:00 am ET
Liminal BioSciences to Divest Bioseparations Division to KKR
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 4, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today the signature of a binding share purchase agreement for the divestment (the "Proposed Sale") of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd ("PBL") to KKR, a leading global investme
Oct 29, 2019 08:00 am ET
Liminal BioSciences announces upcoming presentations new data on pulmonary arterial hypertension at the 2019 AHA meeting
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 29, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF)  ("Liminal BioSciences" or the "Company"), a clinical-stage small molecules company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today the presentation of two scientific posters with new preclinical development in the treatment of pulmonary arterial hypertension ("PAH") at the American Heart Association ("AHA") 2019 Annual Meeting. The conference will take place on November 1
Oct 25, 2019 08:00 am ET
Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 25, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL)  ("Liminal BioSciences" or the "Company"), a clinical-stage small molecules company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the presentation of three abstracts related to the Company's pre-clinical development activities for the treatment of liver diseases at the The Liver Meeting 2019 of the American Association for the Study of Liver Diseases (The Liver Meeting®). The conferenc
Oct 24, 2019 08:00 am ET
Liminal BioSciences Announces Upcoming Presentations at ASN Kidney Week 2019
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 24, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the Company and its' collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology's ("ASN") Kidney Week 2019. The conference will take place on N
Oct 18, 2019 06:00 pm ET
Liminal BioSciences to Present At H.C. Wainwright & Co. 3rd Annual NASH Investor Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 18, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a clinical-stage small molecules company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today, that members of the management team will provide a presentation on PBI-4547 as a potential treatment for NASH at the H.C. Wainwright & Co. 3rd Annual NASH Investor Conference at 16:20 ET on Monday, October 21, 2019 in New York, USA.